Browse LILRB1

Summary
SymbolLILRB1
Nameleukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 1
Aliases LIR-1; ILT2; MIR-7; LIR1; CD85j; ILT-2; MIR7; CD85 antigen-like family member J; Ig-like transcript 2; leuko ......
Chromosomal Location19q13.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane Single-pass type I membrane protein ; SUBCELLULAR LOCATION: Isoform 5: Secreted
Domain PF00047 Immunoglobulin domain
PF13895 Immunoglobulin domain
Function

Receptor for class I MHC antigens. Recognizes a broad spectrum of HLA-A, HLA-B, HLA-C and HLA-G alleles. Receptor for H301/UL18, a human cytomegalovirus class I MHC homolog. Ligand binding results in inhibitory signals and down-regulation of the immune response. Engagement of LILRB1 present on natural killer cells or T-cells by class I MHC molecules protects the target cells from lysis. Interaction with HLA-B or HLA-E leads to inhibition of the signal triggered by FCER1A and inhibits serotonin release. Inhibits FCGR1A-mediated phosphorylation of cellular proteins and mobilization of intracellular calcium ions.

> Gene Ontology
 
Biological Process GO:0001501 skeletal system development
GO:0001818 negative regulation of cytokine production
GO:0001820 serotonin secretion
GO:0001906 cell killing
GO:0001909 leukocyte mediated cytotoxicity
GO:0001910 regulation of leukocyte mediated cytotoxicity
GO:0001911 negative regulation of leukocyte mediated cytotoxicity
GO:0001913 T cell mediated cytotoxicity
GO:0001914 regulation of T cell mediated cytotoxicity
GO:0001915 negative regulation of T cell mediated cytotoxicity
GO:0002228 natural killer cell mediated immunity
GO:0002230 positive regulation of defense response to virus by host
GO:0002237 response to molecule of bacterial origin
GO:0002250 adaptive immune response
GO:0002263 cell activation involved in immune response
GO:0002285 lymphocyte activation involved in immune response
GO:0002286 T cell activation involved in immune response
GO:0002290 gamma-delta T cell activation involved in immune response
GO:0002291 T cell activation via T cell receptor contact with antigen bound to MHC molecule on antigen presenting cell
GO:0002309 T cell proliferation involved in immune response
GO:0002366 leukocyte activation involved in immune response
GO:0002367 cytokine production involved in immune response
GO:0002374 cytokine secretion involved in immune response
GO:0002440 production of molecular mediator of immune response
GO:0002443 leukocyte mediated immunity
GO:0002449 lymphocyte mediated immunity
GO:0002456 T cell mediated immunity
GO:0002460 adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0002521 leukocyte differentiation
GO:0002573 myeloid leukocyte differentiation
GO:0002683 negative regulation of immune system process
GO:0002694 regulation of leukocyte activation
GO:0002695 negative regulation of leukocyte activation
GO:0002696 positive regulation of leukocyte activation
GO:0002697 regulation of immune effector process
GO:0002698 negative regulation of immune effector process
GO:0002699 positive regulation of immune effector process
GO:0002700 regulation of production of molecular mediator of immune response
GO:0002701 negative regulation of production of molecular mediator of immune response
GO:0002703 regulation of leukocyte mediated immunity
GO:0002704 negative regulation of leukocyte mediated immunity
GO:0002706 regulation of lymphocyte mediated immunity
GO:0002707 negative regulation of lymphocyte mediated immunity
GO:0002709 regulation of T cell mediated immunity
GO:0002710 negative regulation of T cell mediated immunity
GO:0002715 regulation of natural killer cell mediated immunity
GO:0002716 negative regulation of natural killer cell mediated immunity
GO:0002718 regulation of cytokine production involved in immune response
GO:0002719 negative regulation of cytokine production involved in immune response
GO:0002739 regulation of cytokine secretion involved in immune response
GO:0002740 negative regulation of cytokine secretion involved in immune response
GO:0002761 regulation of myeloid leukocyte differentiation
GO:0002762 negative regulation of myeloid leukocyte differentiation
GO:0002764 immune response-regulating signaling pathway
GO:0002765 immune response-inhibiting signal transduction
GO:0002767 immune response-inhibiting cell surface receptor signaling pathway
GO:0002768 immune response-regulating cell surface receptor signaling pathway
GO:0002774 Fc receptor mediated inhibitory signaling pathway
GO:0002819 regulation of adaptive immune response
GO:0002820 negative regulation of adaptive immune response
GO:0002822 regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0002823 negative regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0002831 regulation of response to biotic stimulus
GO:0006816 calcium ion transport
GO:0006837 serotonin transport
GO:0006898 receptor-mediated endocytosis
GO:0007159 leukocyte cell-cell adhesion
GO:0007162 negative regulation of cell adhesion
GO:0009306 protein secretion
GO:0009615 response to virus
GO:0010721 negative regulation of cell development
GO:0010959 regulation of metal ion transport
GO:0014062 regulation of serotonin secretion
GO:0014063 negative regulation of serotonin secretion
GO:0015844 monoamine transport
GO:0015850 organic hydroxy compound transport
GO:0019835 cytolysis
GO:0022407 regulation of cell-cell adhesion
GO:0022408 negative regulation of cell-cell adhesion
GO:0022409 positive regulation of cell-cell adhesion
GO:0030099 myeloid cell differentiation
GO:0030100 regulation of endocytosis
GO:0030316 osteoclast differentiation
GO:0031341 regulation of cell killing
GO:0031342 negative regulation of cell killing
GO:0031348 negative regulation of defense response
GO:0031623 receptor internalization
GO:0032479 regulation of type I interferon production
GO:0032480 negative regulation of type I interferon production
GO:0032496 response to lipopolysaccharide
GO:0032606 type I interferon production
GO:0032608 interferon-beta production
GO:0032609 interferon-gamma production
GO:0032613 interleukin-10 production
GO:0032615 interleukin-12 production
GO:0032640 tumor necrosis factor production
GO:0032648 regulation of interferon-beta production
GO:0032649 regulation of interferon-gamma production
GO:0032653 regulation of interleukin-10 production
GO:0032655 regulation of interleukin-12 production
GO:0032680 regulation of tumor necrosis factor production
GO:0032688 negative regulation of interferon-beta production
GO:0032689 negative regulation of interferon-gamma production
GO:0032693 negative regulation of interleukin-10 production
GO:0032695 negative regulation of interleukin-12 production
GO:0032720 negative regulation of tumor necrosis factor production
GO:0032943 mononuclear cell proliferation
GO:0032944 regulation of mononuclear cell proliferation
GO:0032945 negative regulation of mononuclear cell proliferation
GO:0035546 interferon-beta secretion
GO:0035547 regulation of interferon-beta secretion
GO:0035548 negative regulation of interferon-beta secretion
GO:0036035 osteoclast development
GO:0036037 CD8-positive, alpha-beta T cell activation
GO:0038044 transforming growth factor-beta secretion
GO:0042035 regulation of cytokine biosynthetic process
GO:0042036 negative regulation of cytokine biosynthetic process
GO:0042089 cytokine biosynthetic process
GO:0042095 interferon-gamma biosynthetic process
GO:0042098 T cell proliferation
GO:0042107 cytokine metabolic process
GO:0042110 T cell activation
GO:0042129 regulation of T cell proliferation
GO:0042130 negative regulation of T cell proliferation
GO:0042267 natural killer cell mediated cytotoxicity
GO:0042268 regulation of cytolysis
GO:0042269 regulation of natural killer cell mediated cytotoxicity
GO:0042533 tumor necrosis factor biosynthetic process
GO:0042534 regulation of tumor necrosis factor biosynthetic process
GO:0042536 negative regulation of tumor necrosis factor biosynthetic process
GO:0043112 receptor metabolic process
GO:0043271 negative regulation of ion transport
GO:0043900 regulation of multi-organism process
GO:0043903 regulation of symbiosis, encompassing mutualism through parasitism
GO:0045072 regulation of interferon-gamma biosynthetic process
GO:0045077 negative regulation of interferon-gamma biosynthetic process
GO:0045088 regulation of innate immune response
GO:0045637 regulation of myeloid cell differentiation
GO:0045638 negative regulation of myeloid cell differentiation
GO:0045670 regulation of osteoclast differentiation
GO:0045671 negative regulation of osteoclast differentiation
GO:0045785 positive regulation of cell adhesion
GO:0045786 negative regulation of cell cycle
GO:0045806 negative regulation of endocytosis
GO:0045824 negative regulation of innate immune response
GO:0045919 positive regulation of cytolysis
GO:0045953 negative regulation of natural killer cell mediated cytotoxicity
GO:0046629 gamma-delta T cell activation
GO:0046631 alpha-beta T cell activation
GO:0046634 regulation of alpha-beta T cell activation
GO:0046636 negative regulation of alpha-beta T cell activation
GO:0046643 regulation of gamma-delta T cell activation
GO:0046645 positive regulation of gamma-delta T cell activation
GO:0046651 lymphocyte proliferation
GO:0050663 cytokine secretion
GO:0050670 regulation of lymphocyte proliferation
GO:0050672 negative regulation of lymphocyte proliferation
GO:0050688 regulation of defense response to virus
GO:0050691 regulation of defense response to virus by host
GO:0050707 regulation of cytokine secretion
GO:0050708 regulation of protein secretion
GO:0050709 negative regulation of protein secretion
GO:0050710 negative regulation of cytokine secretion
GO:0050777 negative regulation of immune response
GO:0050792 regulation of viral process
GO:0050863 regulation of T cell activation
GO:0050865 regulation of cell activation
GO:0050866 negative regulation of cell activation
GO:0050867 positive regulation of cell activation
GO:0050868 negative regulation of T cell activation
GO:0050870 positive regulation of T cell activation
GO:0051048 negative regulation of secretion
GO:0051051 negative regulation of transport
GO:0051224 negative regulation of protein transport
GO:0051249 regulation of lymphocyte activation
GO:0051250 negative regulation of lymphocyte activation
GO:0051251 positive regulation of lymphocyte activation
GO:0051607 defense response to virus
GO:0051924 regulation of calcium ion transport
GO:0051926 negative regulation of calcium ion transport
GO:0060348 bone development
GO:0060627 regulation of vesicle-mediated transport
GO:0061515 myeloid cell development
GO:0070486 leukocyte aggregation
GO:0070489 T cell aggregation
GO:0070661 leukocyte proliferation
GO:0070663 regulation of leukocyte proliferation
GO:0070664 negative regulation of leukocyte proliferation
GO:0070838 divalent metal ion transport
GO:0071216 cellular response to biotic stimulus
GO:0071219 cellular response to molecule of bacterial origin
GO:0071222 cellular response to lipopolysaccharide
GO:0071396 cellular response to lipid
GO:0071593 lymphocyte aggregation
GO:0071706 tumor necrosis factor superfamily cytokine production
GO:0071887 leukocyte apoptotic process
GO:0072511 divalent inorganic cation transport
GO:0072608 interleukin-10 secretion
GO:0072610 interleukin-12 secretion
GO:0072641 type I interferon secretion
GO:0072643 interferon-gamma secretion
GO:0097028 dendritic cell differentiation
GO:0097048 dendritic cell apoptotic process
GO:0098542 defense response to other organism
GO:0098751 bone cell development
GO:1902105 regulation of leukocyte differentiation
GO:1902106 negative regulation of leukocyte differentiation
GO:1903010 regulation of bone development
GO:1903011 negative regulation of bone development
GO:1903037 regulation of leukocyte cell-cell adhesion
GO:1903038 negative regulation of leukocyte cell-cell adhesion
GO:1903039 positive regulation of leukocyte cell-cell adhesion
GO:1903531 negative regulation of secretion by cell
GO:1903555 regulation of tumor necrosis factor superfamily cytokine production
GO:1903556 negative regulation of tumor necrosis factor superfamily cytokine production
GO:1903706 regulation of hemopoiesis
GO:1903707 negative regulation of hemopoiesis
GO:1904950 negative regulation of establishment of protein localization
GO:2000106 regulation of leukocyte apoptotic process
GO:2000107 negative regulation of leukocyte apoptotic process
GO:2000668 regulation of dendritic cell apoptotic process
GO:2000669 negative regulation of dendritic cell apoptotic process
GO:2001179 regulation of interleukin-10 secretion
GO:2001180 negative regulation of interleukin-10 secretion
GO:2001182 regulation of interleukin-12 secretion
GO:2001183 negative regulation of interleukin-12 secretion
GO:2001185 regulation of CD8-positive, alpha-beta T cell activation
GO:2001186 negative regulation of CD8-positive, alpha-beta T cell activation
GO:2001188 regulation of T cell activation via T cell receptor contact with antigen bound to MHC molecule on antigen presenting cell
GO:2001189 negative regulation of T cell activation via T cell receptor contact with antigen bound to MHC molecule on antigen presenting cell
GO:2001191 regulation of gamma-delta T cell activation involved in immune response
GO:2001193 positive regulation of gamma-delta T cell activation involved in immune response
GO:2001198 regulation of dendritic cell differentiation
GO:2001199 negative regulation of dendritic cell differentiation
GO:2001201 regulation of transforming growth factor-beta secretion
GO:2001202 negative regulation of transforming growth factor-beta secretion
GO:2001204 regulation of osteoclast development
GO:2001205 negative regulation of osteoclast development
Molecular Function GO:0008157 protein phosphatase 1 binding
GO:0019902 phosphatase binding
GO:0019903 protein phosphatase binding
GO:0030107 HLA-A specific inhibitory MHC class I receptor activity
GO:0030109 HLA-B specific inhibitory MHC class I receptor activity
GO:0032393 MHC class I receptor activity
GO:0032396 inhibitory MHC class I receptor activity
GO:0042169 SH2 domain binding
GO:0042287 MHC protein binding
GO:0042288 MHC class I protein binding
Cellular Component GO:0009897 external side of plasma membrane
GO:0098552 side of membrane
> KEGG and Reactome Pathway
 
KEGG hsa04380 Osteoclast differentiation
Reactome R-HSA-1280218: Adaptive Immune System
R-HSA-168256: Immune System
R-HSA-198933: Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
Summary
SymbolLILRB1
Nameleukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 1
Aliases LIR-1; ILT2; MIR-7; LIR1; CD85j; ILT-2; MIR7; CD85 antigen-like family member J; Ig-like transcript 2; leuko ......
Chromosomal Location19q13.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between LILRB1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between LILRB1 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
27777574Colorectal carcinomaInhibit immunityCRC-NK cells displayed underexpression of CD16, NKG2D, DNAM-1, CD161, NKp46, and NKp30 activating receptors, while inhibitory receptors CD85j and NKG2A were overexpressed. This inhibited phenotype affected cytotoxic functionality against CRC cells and interferon-γ production.
29180808Ovarian Carcinoma; Colon CarcinomaInhibit immunity; candidate for immunotherapy targetEngagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy. Our results demonstrated that expression of the common MHC class I component β2-microglobulin (β2M) by cancer cells directly protected them from phagocytosis. We further showed that this protection was mediated by the inhibitory receptor LILRB1, whose expression was upregulated on the surface of macrophages, including tumor-associated macrophages.
Summary
SymbolLILRB1
Nameleukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 1
Aliases LIR-1; ILT2; MIR-7; LIR1; CD85j; ILT-2; MIR7; CD85 antigen-like family member J; Ig-like transcript 2; leuko ......
Chromosomal Location19q13.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of LILRB1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolLILRB1
Nameleukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 1
Aliases LIR-1; ILT2; MIR-7; LIR1; CD85j; ILT-2; MIR7; CD85 antigen-like family member J; Ig-like transcript 2; leuko ......
Chromosomal Location19q13.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of LILRB1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.0750.862
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.2810.806
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.3370.714
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.1280.808
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.1110.945
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.4420.847
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.6330.208
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15111.050.356
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.1280.922
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.7450.463
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.1380.469
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0340.86
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of LILRB1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141705.9-5.91
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103033.3-33.30.231
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277311.15.55.60.384
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275911.16.84.30.673
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21179.55.93.61
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)86250250.473
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.16.24.91
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 592011.18.91
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.37.4-2.11
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.17.71.41
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161407.1-7.10.467
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolLILRB1
Nameleukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 1
Aliases LIR-1; ILT2; MIR-7; LIR1; CD85j; ILT-2; MIR7; CD85 antigen-like family member J; Ig-like transcript 2; leuko ......
Chromosomal Location19q13.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of LILRB1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolLILRB1
Nameleukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 1
Aliases LIR-1; ILT2; MIR-7; LIR1; CD85j; ILT-2; MIR7; CD85 antigen-like family member J; Ig-like transcript 2; leuko ......
Chromosomal Location19q13.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of LILRB1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by LILRB1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolLILRB1
Nameleukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 1
Aliases LIR-1; ILT2; MIR-7; LIR1; CD85j; ILT-2; MIR7; CD85 antigen-like family member J; Ig-like transcript 2; leuko ......
Chromosomal Location19q13.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of LILRB1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolLILRB1
Nameleukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 1
Aliases LIR-1; ILT2; MIR-7; LIR1; CD85j; ILT-2; MIR7; CD85 antigen-like family member J; Ig-like transcript 2; leuko ......
Chromosomal Location19q13.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of LILRB1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolLILRB1
Nameleukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 1
Aliases LIR-1; ILT2; MIR-7; LIR1; CD85j; ILT-2; MIR7; CD85 antigen-like family member J; Ig-like transcript 2; leuko ......
Chromosomal Location19q13.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between LILRB1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolLILRB1
Nameleukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 1
Aliases LIR-1; ILT2; MIR-7; LIR1; CD85j; ILT-2; MIR7; CD85 antigen-like family member J; Ig-like transcript 2; leuko ......
Chromosomal Location19q13.4
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting LILRB1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.